Responsible Conduct of Research & Scholarly Activity

News of financial entanglements among biomedical companies and researchers has increasingly called into question the worth and integrity of medical studies, nearly three-fifths of which are funded by industry. This volume assesses the ethical, quantitative, and qualitative questions posed by the current financing of biomedical research. The ten essays collected here reflect the wide range of opinions about perceived financial conflicts of interest in medical studies. The opening section provides an overview of the issue, describing the origins of, and concerns raised by, dubious financial arrangements; explaining how certain common situations intensify problematic funding structures; weighing the risks and benefits of commercialized research funding; and detailing the nature, extent, and consequences of the present relationship among academe, government, and industry in the health sciences. The second section compares how the idea of conflicts of interest differs in biomedical research, legal work, and journalism. It includes a challenging look at the term itself and an argument for managed financial incentives. The final section describes and analyzes the existing regulatory regime, poses questions and directions for future self and external regulation, and provides perspectives from a third-party research company. This considered, balanced discussion will interest scholars of bioethics, public health, and health policy.

Collaborations of physicians and researchers with industry can provide valuable benefits to society, particularly in the translation of basic scientific discoveries to new therapies and products. Recent reports and news stories have, however, documented disturbing examples of relationships and practices that put at risk the integrity of medical research, the objectivity of professional education, the quality of patient care, the soundness of clinical practice guidelines, and the public's trust in medicine. Conflict of Interest in Medical Research, Education, and Practice provides a comprehensive look at conflict of interest in medicine. It offers principles to inform the design of policies to identify, limit, and manage conflicts of interest without damaging constructive collaboration with industry. It calls for both short-term actions and long-term commitments by institutions and individuals, including leaders of academic medical centers, professional societies, patient advocacy groups, government agencies, and drug, device, and pharmaceutical companies. Failure of the medical community to take convincing action on conflicts of interest invites additional legislative or regulatory measures that may be overly broad or unduly burdensome. Conflict of Interest in Medical Research, Education, and Practice makes several recommendations for strengthening conflict of interest policies and curbing relationships that create risks with little benefit. The book will serve as an invaluable resource for individuals and organizations committed to high ethical standards in all realms of medicine.

Modern science is big business. Governments, universities, and corporations have invested billions of dollars in scientific and technological research in the hope of obtaining power and profit. For the most part, this investment has benefited science and society, leading to new discoveries,inventions, disciplines, specialties, jobs, and career opportunities. However, there is a dark side to the influx of money into science. Unbridled pursuit of financial gain in science can undermine scientific norms, such as objectivity, honesty, openness, respect for research participants, andsocial responsibility. In The Price of Truth, David B. Resnik examines some of the important and difficult questions resulting from the financial and economic aspects of modern science. How does money affect scientific research? Have scientists become entrepreneurs bent on making money instead of investigators searchingfor the truth? How does the commercialization of research affect the public's perception of science? Can scientists prevent money from corrupting the research enterprise? What types of rules, polices, and guidelines should scientists adopt to prevent financial interests from adversely affectingresearch and the public's opinion of science?

Winner of the Writers' Trust of Canada's Shaughnessy Cohen Prize for Political Writing and the Canadian Science Writers' Association's Science in Society Book Award. Poison-pen letters, possible medical misconduct and a swirl of competing accusations that led to two inquiries - the Olivieri affair ended careers and shook the international research establishment. A riveting anatomy of Canada's most controversial drug trial, by the medical journalist who helped break the story. In August 1998, a medical scandal erupted in the national and international media whose consequences still reverberate. A charismatic young doctor named Nancy Olivieri, working with young people who suffered from a rare blood disorder, stated that she had discovered serious problems with an experimental drug manufactured by Canada's largest drug company, Apotex. Though her research contract required her to remain silent, she decided she had no choice but to warn the patients enrolled in her trials. Apotex retaliated by cancelling her research and slamming her reputation. In the aftermath, Olivieri became a whistleblower applauded in academia and the media for standing up to powerful corporate interests. The Olivieri affair spawned two inquiries and multiple lawsuits, but the full story of Canada's biggest science scandal has never been told - until now. In the hands of psychiatrist and medical journalist Miriam Shuchman, the debacle over the pill called L1 is revealed as a modern morality play in which every crack in the system of scientific research, corporate financing and peer review stands out in stark relief. By talking with the people whom both Olivieri and Apotex wanted to heal - the youngmen and women struggling to have normal lives despite debilitating treatment - Shuchman also brings us the moving story of the toll on patients' health when battles break out among the physicians and researchers aiming to heal them.

Something has changed in the culture and values of academic science over the last quarter-century. University science is now entangled with entrepreneurship, and researchers with a commercial interest are caught in an ethical quandary. How can an academic scientist honor knowledge for its own sake, while also using knowledge as a means to generate wealth? Science in the Private Interest investigates the trends and effects of modern, commercialized academic science. This book dives unhesitatingly into some of modern science's messiest and most urgent questions. How did scientists begin choosing proprietary gain over the pursuit of knowledge? What effects have academic-corporate partnerships had on the quality and integrity of science? And, most importantly, how does this affect the public?